 |
|
|
| |
Efficacy and Safety of Tenofovir Alafenamide in HIV-Infected Black Adults: Subgroup Analysis of a Randomized, Double-blind Switch Study
|
| |
| |
Reported by Jules Levin
IDWeek Oct 26-30 2016 New Orleans
Edwin DeJesus,1 Rick Ellion,2 Moti Ramgopal,3 Barbara Wade,4 Louis Sloan,5 Howard Edelstein,6 Gerald Pierone,7 Jihad Slim,8 Jeffrey Stephens,9 Mingjin Yan,10 Cecilia Tran-Muchowski,10 Martin Rhee10
1Orlando Immunology Center, Orlando, FL; 2Whitman-Walker Health, Washington, DC; 3Midway Immunology and Research Center, Fort Pierce, FL; 4Infectious Diseases Associates of Northwest Florida PA, Pensacola, FL; 5North Texas Infectious Diseases Consultants, Dallas, TX; 6Alameda Health System-Highland Hospital, Oakland, CA; 7AIDS Research & Treatment Center of the Treasure Coast, Vero Beach, FL; 8Saint Michael's Medical Center, Newark, NJ; 9Mercer University School of Medicine, Macon, GA; 10Gilead Sciences, Inc., Foster City, CA
1. Gunthard HF, et al. JAMA 2016;316:191-210.
2. AIDSinfo, 2016.
https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
3. British HIV Association, 2016.
http://www.bhiva.org/documents/Guidelines/Treatment/2016/treatment-guidelines-2016-interim-update.pdf.
4. Gallant JE, et al. Lancet HIV 2016;3:e158-65.
5. Genvoya [SmPC]. Foster City, CA: Gilead Sciences, Inc., 2015.
6. Odefsey [SmPC]. Foster City, CA: Gilead Sciences, Inc., 2016.
7. Centers for Disease Control and Prevention, 2016.
http://www.cdc.gov/hiv/group/racialethnic/africanamericans/index.html.
8. Choi AI, et al. Am J Med 2009;122:672-8.
|
| |
|
|
|
|
|
